Business Finland

Business Finland R&D funding for healthtech and medical AI

How Business Finland R&D funding fits healthtech and medical AI — cost patterns around validation and compliance, and the clinical and regulatory uncertainties that qualify.

Healthtech and medical AI carry an unusually rich supply of genuine R&D uncertainty — clinical, technical, and regulatory at once — which is good for a funding case. The complication is separating the development R&D that Business Finland funds from the regulatory and clinical processes it doesn’t, and structuring a project that respects both.

Where the uncertainty is genuine

Medical AI rarely lacks uncertainty; the work is often intrinsically uncertain:

can the model achieve clinically acceptable accuracy, sensitivity, and specificity on real, heterogeneous patient data?
can it stay reliable across populations, sites, and equipment rather than overfitting to one dataset?
can it be made explainable and safe enough to support clinical decisions?
can it work within the data constraints that privacy and small clinical datasets impose?

These are real development questions where failure is a genuine possibility — the core of a strong R&D case.

The line Business Finland funds — and the line it doesn’t

This is the segment-specific subtlety. Business Finland funds the development and technical validation of your AI capability. It does not fund the regulatory approval process itself — clinical trials for market authorisation, CE marking as a compliance activity, and formal regulatory submissions are not R&D in the funded sense; they are commercialisation and compliance.

The distinction in practice: developing and technically validating a model whose performance is genuinely uncertain is R&D. Running the formal regulatory pathway to bring an already-working device to market is not. Keep your project scoped to the former.

Cost patterns for healthtech applications

Personnel — data science, engineering, and clinical/domain expertise; the dominant line.
Data — access to, or creation of, clinical datasets for the R&D, handled within strict privacy and compliance rules. Data work is often unusually central and costly here.
Subcontracting — specialist clinical, statistical, or validation expertise, kept a justified minority.
Compliance-adjacent work — be careful: build the technical validation into the R&D, but don’t try to fund the regulatory submission process as if it were development.

The data reality

Medical AI R&D is frequently data-constrained, and this is often the most honest, fundable uncertainty a healthtech company has: whether acceptable clinical performance is achievable given limited, sensitive, and hard-to-obtain data. Make that constraint explicit — it’s a strength in the R&D narrative, not a weakness to hide.

The traps

Framing regulatory work as R&D. The most common healthtech error. Scope it out.
Underestimating the data and privacy load. Build the compliant data pipeline into the plan; it’s often a work package in its own right.
Overclaiming clinical outcomes. Promise technical validation and development, not clinical proof of efficacy you can’t deliver within the project.

Before you apply

Draw a clean line between the AI you’re developing and validating technically (fundable) and the regulatory and clinical approval you’ll pursue afterward (not fundable here). Center the application on the genuine, often data-driven, uncertainty in that first half.